Oral Presentations at the 10th Canadian Conference on Dementia (CCD) Québec City October 3 2019

摘要

Gantenerumab, a fully human monoclonal antibody, is under investigation as a disease-modifying treatment for Alzheimer’s disease (AD). In the ongoing SCarlet RoAD (SR [ ]) and Marguerite RoAD (MR [ ]) open-label extension (OLE) studies, patients with AD who received gantenerumab uptitrated to subcutaneous doses ≤1200 mg monthly for 2 years exhibited high levels of PET amyloid reduction, such that 52% of patients improved below the amyloid positivity threshold. Here we explore the relationship between amyloid reduction and clinical outcomes during the MR and SR OLE studies